[PDF] Top 20 The value of trabectedin in the treatment of soft tissue sarcoma

... to treatment with doxorubicin and ...Furthermore, trabectedin discontinuation in patients with non-progressive disease is not ...of trabectedin with other ... See full document

... that trabectedin used as a single agent is not correlated with any grade of toxicity in about 91% of cases, with grade 3 and 4 adverse events occur- ring in only about 10% of ...of trabectedin and tend to ... See full document

... Abstract: Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mes- enchymal ...systemic treatment in advanced and metastatic soft tissue sarcomas, with an ... See full document

... Centre Sarcoma Group [6]), primary site, presence of bone metastases at the time of diagnosis, number (equal or less than 5, more than 5) and site of bone metastases, treatments received for bone lesions ... See full document

... that trabectedin is a safe and effective therapeutic option in STS with specific efficacy in myxoid/round cell sarcoma, and LMS (Table ...as sarcoma, complicated by the lack of good therapeutic ... See full document

... standard treatment has yet emerged after failure of doxorubicin containing chemotherapy though some agents such as gemcitabine and gemcitabine-docetaxel combination have shown promising results (Patel et al 2001; ... See full document

... The treatment is generally well tolerated at the recommended ...of trabectedin and its effect on transcription pathways make it a good candidate for combination with other chemothera- peutic agents or ... See full document

... The better comprehension of STS biology led to the identification of several biological mechanisms poten- tially applicable in new drug development. The value of mammalian target of rapamycin (mTOR) inhibition in ... See full document

... for trabectedin and combination groups for IB115 and n = 5 for vehicle and rucaparib groups and n = 8 for trabectedin and combination groups in PDX) 2 weeks after the tumor became meas- urable (15 days ... See full document

... The strength of this study lies in the use of two vali- dated scores for measuring patients’ QoL after TM-ILP treatment. One of the drawbacks of this study is its se- lection bias and the rather small number of ... See full document

... with trabectedin in a consecutive series of pretreated ...study treatment until disease progression, as shown by radiological or clinical examination, or death from any ...study treatment until death ... See full document

... received trabectedin in the context of clinical trials, compassionate use programs, expanded access programs, or in standard clinical ...seriously, treatment-related deaths were reported, which in some ... See full document

... The baseline estimates of quantitative MRI parameters reported in this cohort of 30 patients, together with their repeatability, provide essential information for planning multi-parametric imaging studies in ... See full document

... refractory sarcoma also demonstrated a PFS but not OS ...different treatment goals, and dif- ferent histologic STS ...that trabectedin, pazopanib, and eribulin do not generate signifi- cant shrinkage ... See full document

... the treatment of patients with STS who progress on or are not candidates for anthracycline- or ifosfamide-based ...to trabectedin in patients unlikely to benefit from other standard- of-care ...of ... See full document

... The Phase II primary end point was PFS. It was 6.6 months (95% CI 4.1–8.3 months) for patients treated with olaratumab plus doxorubicin and 4.1 months (95% CI 2.8–5.4 months) for those treated with doxorubicin ... See full document

... a treatment, in virtue of provid- ing management of symptoms related to disease, such as shortness of breath or ...that trabectedin, pazopanib, and eribulin did not show significant response rate and ... See full document

... A randomized, placebo-controlled Phase III trial has shown that pazopanib has activity in advanced pretreated STS. The drug is well tolerated, allowing prolonged therapy. The drug has been approved for patients with ... See full document

... the treatment of these rare tumors has remained remarkably homogeneous, and systemic chemotherapy including agents such as doxorubicin or ifosfamide remains, for the moment, the ...with sarcoma subtypes, ... See full document

... tumour soft-tissue ...in soft-tissue sarcomas is challenging: there are more than 70 different histological subtypes, with heterogeneous genetic make-up and clinical behaviour including age at ... See full document